Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 10
Submit an article Journal homepage
2,299
Views
3
CrossRef citations to date
0
Altmetric
Cardiovascular

Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark

Trine Pilgaarda Pfizer Denmark, Health and Value, Ballerup, DenmarkCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1771-956X
ORCID Icon,
Mikkel Hasse Pedersenb Incentive, Holte, DenmarkORCID Iconhttps://orcid.org/0000-0002-3568-767X
ORCID Icon &
Steen Hvitfeldt Poulsenc Department of Cardiology, Aarhus University Hospital, Aarhus, DenmarkORCID Iconhttps://orcid.org/0000-0002-9586-835X
ORCID Icon
Pages 1084-1091 | Received 18 May 2020, Accepted 22 Jun 2020, Published online: 11 Jul 2020

References

  • Ruberg F, Berk J. Transthyretin (TTR) Cardiac Amyloidosis. Circulation. 2012;126(10):1286–1300.
  • Grogan M, Scott C, Kyle R, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–1020.
  • Damy T, Kristen A, Suhr O, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J. 2019. DOI:10.1093/eurheartj/ehz173
  • Connors L, Doros G, Sam F, et al. Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid. 2011;18(sup1):157–159.
  • González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38(24):1895–1904.
  • Bhogal S, Ladia V, Sitwala P, et al. Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 2018;43(1):10–34.
  • Mohamed-Salem L, Santos-Mateo J, Sanchez-Serna J, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018;270:192–196.
  • Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–239.
  • Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26.
  • Ladefoged B, Dybro A, Povlsen J, et al. Diagnostic delay in wild type transthyretin cardiac amyloidosis – A clinical challenge. Int J Cardiol. 2020;304:138–143.
  • Bishop E, Brown E, Fajardo J, et al. Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid. 2018;25(3):174–179.
  • Bundgaard J, Mogensen U, Christensen S, et al. The economic burden of heart failure in Denmark from 1998 to 2016. Eur J Heart Fail. 2019;21(12):1526–1531.
  • Maurer M, Schwartz J, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
  • Sundhedsdatastyrelsen. Interaktiv DRG 2020. http://drgservice.ssi.dk/grouper/Modules/Home/. (accessed May 5, 2020).
  • Ankjaer-Jensen A, Rosling P, Bilde L. Variable prospective financing in the Danish hospital sector and the development of a Danish case-mix system. Health Care Manag Sci. 2006;9(3):259–268.
  • Givens RC, Russo C, Green P, et al. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health. 2013;9(2):229–235.
  • Ruberg F, Mathew SM, Judge D, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222–228.
  • Gillmore J, Maurer M, Falk R, et al. Nonbiopsy diagnosis of cardiac transthyretin Amyloidosis. Heart Fail. 2016;133(24):2404–2412.
  • Gonzálo-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594.
  • Kirkfeldt R, Johansen J, Nohr E, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35(18):1186–1194.
  • Nativi-Nicolau J, Vieira M, Chen Y, et al. Hospitalizations and Mortality Among Medicare Beneficiaries With Diagnosis of Wild-Type Amyloidosis Cardiomyopathy, Poster presented at AMCP Nexus 2019, National Harbor, Maryland, USA: 2019.
  • Johnsen S, Dalby L, Täckström T, et al. Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res. 2017;17(1):714
  • Jakobsen M, Kolodziejczyk C, Fredslund E, et al. Societal costs of first-incident ischemic stroke in patients with atrial Fibrillation-A Danish Nationwide Registry Study. Value Health. 2016;19(4):413–418.
  • Brogaard S, Nielsen M, Nielsen L, et al. Health care and social care costs of pneumonia in Denmark: a register-based study of all citizens and patients with COPD in three municipalities. Int J Chron Obstruct Pulmon Dis. 2015;10:2303–2309.
  • Danske Regioner. Danske Regioner - Økonomisk Vejledning 2020 n.d. https://www.regioner.dk/aftaler-og-oekonomi/oekonomisk-vejledning/oekonomisk-vejledning-2020. (accessed Jun 7, 2020).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.